Analysis of Chemotherapy Regimens and Survival Rates in Patients with Metastatic Breast Cancer: Retrospective Cross-Sectional Study

Abstract

Background: Metastatic Breast Cancer (MBC) patients requires multimodality treatment with variable treatment regimens and survival rates. MBC care requires chemotherapy, but researchers are still finding the ideal drug combination to limit adverse effects.

Methods: This retrospective cross-sectional study done at NMCH Patna, examined 260 female MBC patients from January 2022 to January 2024. We evaluated demographic data, chemotherapy regimens (including anthracycline-based, taxane-based, platinum-based, and combination therapies), and survival outcomes (including median OS and progression-free survival) using Kaplan-Meier survival analysis and Cox proportional hazards regression.

Results: With 60% of patients having an ECOG performance level of 0 or 1, the majority of patients (65%) were in the 50-65 age range. Sixty one percent of patients tested positive for hormone receptors(ER/PR), while nearly sixty nine percent tested negative for HER2. Combination therapies outperformed anthracycline-, taxane-, and platinum-based regimens in terms of median overall survival (OS) (22 months) and progression-free survival (PFS) (10 months). There were notable variations in survival results among regimens, as shown by statistical analysis (p < 0.05).

Conclusion: The study found that NMCH Patna women with MBC survive better with combination chemotherapy. This study supports the premise that each patient needs a customised treatment. Future prospective studies should include more groups to confirm these findings and refine therapeutic recommendations.